CY1119118T1 - Θεραπευτικος παραγων για τις διαταραχες της διαθεσης - Google Patents

Θεραπευτικος παραγων για τις διαταραχες της διαθεσης

Info

Publication number
CY1119118T1
CY1119118T1 CY20171100798T CY171100798T CY1119118T1 CY 1119118 T1 CY1119118 T1 CY 1119118T1 CY 20171100798 T CY20171100798 T CY 20171100798T CY 171100798 T CY171100798 T CY 171100798T CY 1119118 T1 CY1119118 T1 CY 1119118T1
Authority
CY
Cyprus
Prior art keywords
disorders
therapeutic products
prophylaxis
agent
formula
Prior art date
Application number
CY20171100798T
Other languages
English (en)
Inventor
Koji Yamada
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of CY1119118T1 publication Critical patent/CY1119118T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Παρέχονται ένας παράγων για την αγωγή και/ή την προφύλαξη μίας διαταραχής της διάθεσης ο οποίος περιλαμβάνει, ως δραστικό συστατικό, ένα παράγωγο του θειαζολίου που αναπαριστάται από τον τύπο (I) όπου το R1 αναπαριστά αρύλιο ή παρόμοιο, και το R2 αναπαριστά πυριδύλιο ή παρόμοιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτού, και παρόμοια.
CY20171100798T 2009-09-02 2017-07-26 Θεραπευτικος παραγων για τις διαταραχες της διαθεσης CY1119118T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202893 2009-09-02
PCT/JP2010/064988 WO2011027805A1 (ja) 2009-09-02 2010-09-02 気分障害治療剤

Publications (1)

Publication Number Publication Date
CY1119118T1 true CY1119118T1 (el) 2018-02-14

Family

ID=43649339

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100798T CY1119118T1 (el) 2009-09-02 2017-07-26 Θεραπευτικος παραγων για τις διαταραχες της διαθεσης

Country Status (31)

Country Link
US (1) US9249135B2 (el)
EP (1) EP2474543B1 (el)
JP (1) JP5663484B2 (el)
KR (1) KR101762981B1 (el)
CN (1) CN102482272A (el)
AU (1) AU2010290423B2 (el)
BR (1) BR112012004851B8 (el)
CA (1) CA2772920C (el)
CL (1) CL2012000534A1 (el)
CY (1) CY1119118T1 (el)
DK (1) DK2474543T3 (el)
DO (1) DOP2012000058A (el)
EA (1) EA030333B1 (el)
ES (1) ES2633538T3 (el)
GE (1) GEP20156224B (el)
HR (1) HRP20171137T1 (el)
HU (1) HUE033690T2 (el)
IL (1) IL218321A (el)
LT (1) LT2474543T (el)
MA (1) MA33618B1 (el)
ME (1) ME02804B (el)
MX (1) MX2012002528A (el)
NZ (1) NZ598750A (el)
PL (1) PL2474543T3 (el)
PT (1) PT2474543T (el)
RS (1) RS56345B1 (el)
SI (1) SI2474543T1 (el)
TN (1) TN2012000092A1 (el)
UA (1) UA110097C2 (el)
WO (1) WO2011027805A1 (el)
ZA (1) ZA201202346B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1700856E (pt) * 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
CN112566901A (zh) 2018-06-18 2021-03-26 詹森药业有限公司 作为RORγt的调节剂的苯基取代的吡唑类
CA3103771A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
JP2021529161A (ja) 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレーターとしてのピリジニルピラゾール
US11345666B2 (en) 2018-06-18 2022-05-31 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928386B2 (ja) 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
ATE325610T1 (de) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
EP1631294B1 (en) 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. A method of treating an anxiety disorder
PT1700856E (pt) 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
CN1976905A (zh) 2004-03-30 2007-06-06 大正制药株式会社 嘧啶衍生物以及与其应用有关的治疗方法
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
WO2007015528A1 (ja) 2005-08-02 2007-02-08 Kyowa Hakko Kogyo Co., Ltd. 睡眠障害の治療および／または予防剤

Also Published As

Publication number Publication date
ZA201202346B (en) 2015-11-25
AU2010290423B2 (en) 2015-10-29
BR112012004851B1 (pt) 2021-03-02
BR112012004851A2 (pt) 2016-04-05
BR112012004851B8 (pt) 2021-05-25
ES2633538T3 (es) 2017-09-21
AU2010290423A1 (en) 2012-04-19
EP2474543A1 (en) 2012-07-11
HRP20171137T1 (hr) 2017-10-06
TN2012000092A1 (en) 2013-09-19
LT2474543T (lt) 2017-08-25
EP2474543A4 (en) 2013-05-29
CA2772920A1 (en) 2011-10-03
CL2012000534A1 (es) 2012-09-14
EP2474543B1 (en) 2017-05-03
DOP2012000058A (es) 2012-06-30
IL218321A0 (en) 2012-04-30
US9249135B2 (en) 2016-02-02
KR20120047310A (ko) 2012-05-11
CA2772920C (en) 2018-07-31
ME02804B (me) 2018-01-20
GEP20156224B (en) 2015-01-26
IL218321A (en) 2016-10-31
US20120184554A1 (en) 2012-07-19
RS56345B1 (sr) 2017-12-29
NZ598750A (en) 2014-08-29
CN102482272A (zh) 2012-05-30
MA33618B1 (fr) 2012-09-01
EA030333B1 (ru) 2018-07-31
KR101762981B1 (ko) 2017-07-28
JP5663484B2 (ja) 2015-02-04
JPWO2011027805A1 (ja) 2013-02-04
HUE033690T2 (hu) 2017-12-28
PT2474543T (pt) 2017-08-03
PL2474543T3 (pl) 2017-09-29
WO2011027805A1 (ja) 2011-03-10
EA201270359A1 (ru) 2012-09-28
DK2474543T3 (en) 2017-08-14
SI2474543T1 (sl) 2017-08-31
MX2012002528A (es) 2012-04-11
UA110097C2 (uk) 2015-11-25

Similar Documents

Publication Publication Date Title
CY1119118T1 (el) Θεραπευτικος παραγων για τις διαταραχες της διαθεσης
CY1123569T1 (el) Παραγωγα ισοϊνδολινο-1-ονης ως δραστικοτητα θετικου αλλοστερiκου τροποποιητη χολινεργικου μουσκαρινικου μ1 υποδοχεα για τη θεραπεια της νοσου toy alzheimer
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20140413A (es) Inhibidores de serina/treonina cinasa
CO6480927A2 (es) Derivados de imidazolin-2-ona 1,3-disustituida como inhibidores de cyp17.
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CY1117122T1 (el) Παραγωγα πυραζολοσπειροκετονης για χρηση ως αναστολεις ακετyλ-coa καρβοξυλασης
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
MX367554B (es) Derivados heterocíclicos y sus usos.
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
UA109793C2 (uk) Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
NZ626112A (en) Triazinone compound and t-type calcium channel inhibitor
NZ707832A (en) 2-pyridone compound
CY1115153T1 (el) Μεθοδοι για την αγωγη δερματολογικων διαταραχων